Crucell’s new influenza antibody found to be effective in preclinical study

The preclinical study compared Crucell’s monoclonal antibody (mAb) CR6261 with the anti-influenza drug oseltamivir in terms of their value for flu prevention and treatment. The flu strains tested included the ‘bird flu’ strain H5N1, which, experts fear, has the potential to cause a pandemic, and H1N1, which is similar to the strain responsible for the devastating pandemic in 1918.

According to the company, study data showed that the mAb CR6261 was 100% successful in preventing infection with H5N1. When given after H5N1 infection, Crucell’s mAb reportedly demonstrated the ability to prevent death and cure disease in all cases. The mAb also performed significantly better for the prevention and treatment of H1N1 infection, illustrating the potential use for seasonal applications as well.

Importantly, the study showed that CR6261 provides immediate protection against the influenza virus, suggesting that it will be able to prevent disease spread. In contrast, oseltamivir was less efficacious and in some cases not effective at all, the company added.

Jaap Goudsmit, Crucell’s chief scientific officer, said: An effective treatment of influenza is urgently needed. The limited efficacy of oseltamivir and the rising resistance to this anti-influenza drug are cause for concern. I am very encouraged by these preclinical results indicating that our monoclonal antibody may provide an effective means for disease prevention and cure.